A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications.
Authors
Corrie, PBulusu, R
Wilson, C
Armstrong, G
Bond, S
Hardy, R
Lao-Sirieix, S
Parashar, D
Ahmad, A
Daniel, F
Hill, M
Wilson, Gregory
Blesing, C
Moody, A
McAdam, K
Osborne, M
Affiliation
Oncology Division, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK.Issue Date
2012-08-07
Metadata
Show full item recordAbstract
Pyridoxine is frequently used to treat capecitabine-induced hand-foot syndrome (HFS), although the evidence of benefit is lacking. We performed a randomised placebo-controlled trial to determine whether pyridoxine could avoid the need for capecitabine dose modifications and improve outcomes.Citation
A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications. 2012, 107 (4):585-7 Br J CancerJournal
British Journal of CancerDOI
10.1038/bjc.2012.318PubMed ID
22814578Type
ArticleLanguage
enISSN
1532-1827ae974a485f413a2113503eed53cd6c53
10.1038/bjc.2012.318